News Trial of Bundibugyo Ebola drugs starts in DRC Patients are now being enrolled in a trial of two potential therapies for Bundibugyo Ebola, Mapp's MBP134 and Gilead's remdesivir, says WHO.
News Ibrance cleared in US for 'double-positive' breast cancer Ibrance has become the first CDK4/6 inhibitor to be approved for a challenging subtype of breast cancer that is often resistant to current treatment.
News Astellas' Padcev and Gilead's Trodelvy grab key EU approvals New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.
News FDA starts kicks off review of Gilead's weekly HIV pill The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.
News WHO names three 'priority' Ebola drugs for trials The WHO has named drugs from Regeneron, Mapp Bio, and Gilead that should be fast-tracked through trials to respond to the current Ebola outbreak.
News Datroway is first TROP2 drug for frontline breast cancer AZ and Daiichi's Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
